List of Excipients in Branded Drug KENALOG-40

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	BENZYL ALCOHOL
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	CARBOXYMETHYLCELLULOSE SODIUM
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	HYDROCHLORIC ACID
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	NITROGEN
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	POLYSORBATE 80
ER Squibb & Sons LLC	KENALOG-40	triamcinolone acetonide	0003-0293	SODIUM CHLORIDE

KENALOG-40 Excipient Strategy and Commercial Opportunities

Last updated: August 17, 2026

KENALOG-40 is a 40 mg/mL injectable suspension of triamcinolone acetonide. Its formulation uses benzyl alcohol, polysorbate 80, sodium carboxymethylcellulose, sodium chloride, and water for injection. The commercial opportunity is concentrated in generic or differentiated injectable products that match the reference suspension’s critical quality attributes while improving preservative profile, packaging, convenience, or administration performance.[1]

The largest technical barriers are particle-size control, redispersibility, syringeability, sterility assurance, container compatibility, and demonstration of pharmaceutical equivalence. Since triamcinolone acetonide is an established corticosteroid rather than a biologic, biosimilar pathways do not apply. The competitive route is primarily an abbreviated new drug application, although materially differentiated formulations may require a 505(b)(2) application.

What excipients are used in KENALOG-40?

The labeled KENALOG-40 formulation contains the following excipients:

Excipient	Labeled concentration or role	Primary formulation function	Key commercial issue
Benzyl alcohol	0.99%	Preservative	Neonatal toxicity concerns and potential market preference for preservative-free products
Polysorbate 80	0.04%	Wetting and dispersion aid	Oxidation, peroxide formation, particle-interface effects
Sodium carboxymethylcellulose	0.5%	Suspending and viscosity-enhancing agent	Syringe force, injectability, sedimentation control
Sodium chloride	0.9%	Tonicity adjustment	Osmolality and injection-site tolerability
Water for injection	q.s.	Vehicle	Sterility, endotoxin, and container compatibility

The formulation is an aqueous suspension rather than a solution. The active pharmaceutical ingredient is therefore present as dispersed particles. Excipient selection directly affects sedimentation, aggregation, dose uniformity, resuspension, needle passage, and local tolerability.

KENALOG-40 labeling identifies the product for intramuscular and intra-articular use and warns against intravenous, intradermal, and intraocular administration. The suspension must be shaken before use, which confirms the importance of physical stability and dose uniformity during the product’s use period.[1]

How does the KENALOG-40 excipient system work?

Sodium carboxymethylcellulose controls suspension behavior

Sodium carboxymethylcellulose increases the continuous phase viscosity and slows sedimentation. Its concentration must balance two opposing requirements:

• Higher viscosity can improve suspension stability.
• Excessive viscosity can increase injection force and impair syringeability.

For a 40 mg/mL depot suspension, the polymer also affects sediment compactness. A compact sediment may be difficult to redisperse, while excessive flocculation can cause poor dose uniformity. Generic developers must characterize sedimentation volume, redispersibility, particle-size distribution, and delivered dose after storage.

Polymer molecular weight, degree of substitution, ionic content, and supplier variability can change viscosity even when the nominal concentration remains constant. A dual-source strategy may therefore require a formal comparability program.

Polysorbate 80 supports wetting and dispersion

Polysorbate 80 reduces interfacial tension between triamcinolone acetonide particles and the aqueous vehicle. It can reduce particle agglomeration and improve wetting during manufacturing.

The excipient creates known development risks. Polysorbate 80 can undergo oxidation and hydrolysis, generating degradants that may affect formulation color, odor, subvisible particles, or active-particle interfaces. Peroxide burden in the incoming excipient and oxygen exposure during filling are relevant control points.

A commercial developer may evaluate low-peroxide polysorbate 80, nitrogen overlay, oxygen-controlled filling, and light-protective packaging. These changes can improve stability, but they may also alter particle size or suspension performance and therefore require full pharmaceutical-equivalence assessment.

Benzyl alcohol provides multidose preservation

Benzyl alcohol supports the product’s preserved multidose presentation. Its presence creates a clear differentiation opportunity because preservative exposure is a concern in neonates and certain vulnerable populations. The labeled product is not intended for neonatal use, but the broader injectable market continues to separate preserved multidose products from preservative-free single-dose presentations.

Replacing benzyl alcohol is not a simple excipient substitution. A preservative-free product would normally require a different container strategy, such as a single-dose vial or prefilled syringe, along with revised microbiological controls and a new stability package.

Sodium chloride manages tonicity

Sodium chloride is used to adjust tonicity. It also contributes to ionic strength, which can affect polymer hydration, particle interactions, and suspension stability. A developer changing the tonicity agent must assess more than osmolality. The change may influence flocculation, viscosity, pH drift, and injection-site tolerability.

What formulation opportunities exist for KENALOG-40 competitors?

The strongest commercial opportunities are differentiated presentations that preserve the clinical role of triamcinolone acetonide while reducing handling or tolerability concerns.

Opportunity	Product concept	Regulatory path	Commercial rationale
Preservative-free product	Single-dose vial or prefilled syringe without benzyl alcohol	ANDA possible if pharmaceutical equivalence is established; 505(b)(2) risk if claims or formulation differ materially	Removes benzyl alcohol and supports sensitive-patient positioning
Prefilled syringe	Ready-to-use 1 mL or other fixed-dose presentation	ANDA or 505(b)(2), depending on differences	Reduces preparation steps and dosing errors
Lower-volume presentation	More concentrated suspension or optimized dose volume	Likely 505(b)(2) if strength or dosing differs	Supports office-based procedures and reduces injection volume
Improved resuspension	Controlled flocculation and optimized polymer/surfactant system	ANDA if equivalent; otherwise 505(b)(2)	Reduces shaking time and dose-uniformity risk
Low-force delivery	Needle and syringe combination optimized for suspension flow	Combination-product considerations	Improves administration ergonomics
Alternative container	Polymer syringe, dual-chamber system, or enhanced vial	Depends on device and formulation changes	Differentiates handling, breakage, and waste performance
Supply-chain alternative	Second-source excipient and packaging platform	Standard post-approval controls or new application data	Reduces dependence on single suppliers

A concentrated product would face a material clinical and regulatory burden because triamcinolone acetonide suspension strength, injected volume, and tissue exposure are linked. A lower-volume product may be commercially attractive but would not be a routine generic substitution if it changes dosing instructions or clinical use.

What are the main generic development barriers for triamcinolone acetonide injection?

A generic developer must establish pharmaceutical equivalence to the reference listed drug. For a complex injectable suspension, the relevant evidence extends beyond active ingredient identity and strength.

Key development attributes include:

1. Active and excipient identity.
2. Assay and degradation products.
3. Particle-size distribution and morphology.
4. Sedimentation and redispersibility.
5. Suspension viscosity and syringeability.
6. Delivered dose and dose uniformity.
7. pH and osmolality.
8. Sterility and bacterial endotoxin limits.
9. Visible and subvisible particulate matter.
10. Container-closure integrity.
11. Extractables and leachables.
12. Stability under labeled storage and in-use conditions.

FDA’s generic drug framework requires pharmaceutical equivalence and bioequivalence, with product-specific evidence depending on the dosage form and formulation complexity.[2] For an injectable suspension, conventional pharmacokinetic bioequivalence may not fully capture local depot behavior. FDA can require additional comparative characterization or other evidence where formulation attributes affect drug release.

The most important manufacturing controls are milling or crystallization of the active ingredient, powder wetting, order of addition, shear exposure, polymer hydration, sterile processing, and filling accuracy. The process must produce a reproducible particle population and avoid agglomeration during sterilization or storage.

What FDA regulatory status applies to KENALOG-40?

KENALOG-40 is an FDA-approved prescription corticosteroid injectable suspension marketed under an established drug product. The product is not a biologic, so the Biologics Price Competition and Innovation Act biosimilar pathway does not apply.

The principal regulatory routes are:

ANDA under Section 505(j)

An ANDA is the most direct route for a product that matches the reference listed drug in active ingredient, dosage form, strength, route, and conditions of use. The applicant must demonstrate sameness and bioequivalence under FDA requirements.

The principal risk is that excipient or presentation changes may prevent a finding of pharmaceutical equivalence. A preservative-free product, new strength, new route, or meaningful device change may move development outside a straightforward ANDA strategy.

505(b)(2) application

A 505(b)(2) application may be appropriate for a new formulation, delivery system, preservative-free presentation, new strength, or other modification relying partly on FDA’s prior findings for triamcinolone acetonide.

This route may support differentiated labeling, but it carries greater clinical and regulatory expense than an ANDA. It can also create new intellectual-property opportunities around formulation, device integration, manufacturing, or use.

When does KENALOG-40 lose exclusivity, and what is its patent position?

KENALOG-40 is a legacy small-molecule product with no expected remaining new chemical entity exclusivity. Its commercial protection is therefore driven by manufacturing scale, regulatory approvals, supply reliability, brand recognition, and any later-issued formulation or device rights rather than original active-ingredient exclusivity.

No current patent expiration date should be treated as the principal market-entry constraint for triamcinolone acetonide injection. The relevant diligence questions are:

• Whether the current reference product has Orange Book-listed patents.
• Whether an applicant can certify Paragraph IV against any listed patent.
• Whether a differentiated product creates new patents that are enforceable against later entrants.
• Whether device, container, formulation, or manufacturing patents exist outside the Orange Book.
• Whether state or federal litigation affects approval or launch timing.

The FDA Orange Book is the controlling source for listed patents and regulatory exclusivity associated with approved products.[3] A generic applicant should conduct a current Orange Book and patent-family review before filing. Historical patents covering triamcinolone acetonide chemistry are unlikely to block modern injectable entry because the active ingredient has been used for decades.

What Paragraph IV and litigation risks affect KENALOG-40?

A Paragraph IV challenge is commercially relevant only if an unexpired patent is listed for the reference product. For an old corticosteroid injection, the greater practical risk is usually not patent litigation. It is FDA review of suspension equivalence, manufacturing reproducibility, sterile filling, and product-specific characterization.

Potential litigation areas include:

• Orange Book patent challenges.
• Patent infringement claims involving a new preservative-free formulation.
• Device patents covering prefilled syringes or injection systems.
• Trade-secret disputes over particle engineering or sterile manufacturing.
• Product-liability claims involving injection-site reactions or administration errors.

No biosimilar litigation pathway applies. Settlement agreements would matter only if a listed patent challenge occurred. Any first-filer advantage under the ANDA framework must be confirmed from FDA records and current applicant status rather than inferred from the age of the brand.

How strong is the KENALOG-40 patent estate?

The original product patent estate is commercially weak relative to newer branded drugs because triamcinolone acetonide and its injectable use are long-established. The stronger potential rights are secondary patents covering:

• Specific particle-size distributions.
• Flocculated suspension systems.
• Preservative-free formulations.
• Low-peroxide surfactant systems.
• Prefilled syringe configurations.
• Methods for improving resuspension or injection force.
• Manufacturing processes that reduce aggregation.
• Combination products with procedural devices.

Secondary patents must contain narrow, reproducible technical limitations. Broad claims directed only to triamcinolone acetonide in an aqueous suspension are vulnerable to prior-art and obviousness challenges. Claims tied to measured particle-size ranges, defined excipient ratios, stability performance, or device parameters may provide stronger differentiation if supported by comparative data.

Which companies are challenging or competing with KENALOG-40?

Competition is likely to come from generic manufacturers of triamcinolone acetonide injectable suspension and from alternative corticosteroid injections, including methylprednisolone acetate and betamethasone products. The relevant competitors are not limited to identical 40 mg/mL products because physicians may select among corticosteroid suspensions based on procedure, duration, availability, price, and institutional formulary rules.

The competitive landscape has four segments:

Segment	Competitive basis
Generic triamcinolone acetonide suspension	Price, supply reliability, equivalent labeling
Branded KENALOG-40	Brand familiarity, physician use, distributor access
Alternative corticosteroid suspensions	Clinical preference, duration, formulation, and procedure
Differentiated delivery products	Preservative-free packaging, prefilled delivery, lower handling burden

Standalone KENALOG-40 revenue is not separately disclosed in Bristol Myers Squibb public financial reporting. Revenue exposure should therefore be modeled from unit volume, average selling price, channel mix, and the share of procedures using triamcinolone acetonide rather than from reported company-level figures.

What commercial strategy offers the best return?

The lowest-risk opportunity is a conventional generic with a robust suspension process and reliable sterile manufacturing. This approach offers the fastest potential route but faces price erosion and multiple-entrant competition.

A preservative-free, single-dose product offers a stronger differentiation thesis. Its commercial value depends on whether hospitals, ambulatory surgery centers, dermatology practices, orthopedics clinics, and pain practices will pay for reduced preservative exposure and improved workflow.

A prefilled syringe could create additional value through reduced preparation time and lower medication-error risk. The product must solve suspension-specific issues such as particle settling during storage, needle compatibility, dead volume, and the ability to redisperse the dose without excessive manipulation.

The most defensible platform strategy combines:

• A standard generic vial for broad market access.
• A preservative-free single-dose presentation.
• A prefilled syringe or other administration-focused product.
• Supplier-qualified excipient and container alternatives.
• Patent claims directed to measurable formulation and delivery attributes.

Key Takeaways

• KENALOG-40 is a triamcinolone acetonide 40 mg/mL aqueous injectable suspension.
• Its critical excipients are benzyl alcohol, polysorbate 80, sodium carboxymethylcellulose, sodium chloride, and water for injection.
• Sodium carboxymethylcellulose and polysorbate 80 control suspension performance, while benzyl alcohol enables preserved multidose use.
• The strongest commercial opportunities are preservative-free single-dose packaging, prefilled delivery, improved resuspension, and low-force administration.
• Generic development is technically difficult because particle size, sedimentation, redispersibility, syringeability, sterility, and delivered-dose uniformity must be controlled together.
• KENALOG-40 has no meaningful remaining new chemical entity exclusivity.
• Patent risk is likely to be lower than regulatory and manufacturing risk, although current Orange Book listings and secondary formulation or device patents require transaction-specific review.
• Biosimilar competition is irrelevant because triamcinolone acetonide is a small molecule.
• A standard ANDA is the principal entry route; materially differentiated formulations may require a 505(b)(2) application.

FAQs About KENALOG-40 Excipient and Market Strategy

Is benzyl alcohol essential to the KENALOG-40 formulation?

Benzyl alcohol is the labeled preservative for the multidose product. It is not essential to the active ingredient’s pharmacology, but removing it would require a different presentation and microbiological-control strategy.

Can a generic KENALOG-40 product use different excipients?

A generic may use different inactive ingredients only within FDA’s applicable safety and pharmaceutical-equivalence framework. For a suspension, even small excipient changes can alter particle interactions, viscosity, redispersibility, and delivered dose.

Is a preservative-free triamcinolone injection automatically an ANDA product?

No. A preservative-free product may qualify for an ANDA if it remains pharmaceutically equivalent and meets FDA requirements. A new strength, device, dosing instruction, or clinical claim may require a 505(b)(2) application.

Does KENALOG-40 have biosimilar competition?

No. Biosimilar regulations apply to biological products. KENALOG-40 contains triamcinolone acetonide, a synthetic small-molecule corticosteroid, so competition proceeds through generic and reformulated-drug pathways.

What is the most valuable patent strategy for a new triamcinolone suspension?

The strongest strategy is usually to claim measurable technical attributes, such as particle-size distribution, excipient ratios, suspension stability, injection-force performance, container configuration, or manufacturing controls, supported by comparative data.

References

1. DailyMed. (n.d.). KENALOG-40 injection: Triamcinolone acetonide injectable suspension, USP, 40 mg/mL. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2023). Abbreviated new drug application submissions: Content and format.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. Washington, DC: U.S. Department of Health and Human Services.